Laboratory models of post-traumatic stress disorder: The elusive bridge to translation
- PMID: 35325617
- PMCID: PMC9167267
- DOI: 10.1016/j.neuron.2022.03.001
Laboratory models of post-traumatic stress disorder: The elusive bridge to translation
Abstract
Post-traumatic stress disorder (PTSD) is a debilitating mental illness composed of a heterogeneous collection of symptom clusters. The unique nature of PTSD as arising from a precipitating traumatic event helps simplify cross-species translational research modeling the neurobehavioral effects of stress and fear. However, the neurobiological progress on these complex neural circuits informed by animal models has yet to produce novel, evidence-based clinical treatment for PTSD. Here, we provide a comprehensive overview of popular laboratory models of PTSD and provide concrete ideas for improving the validity and clinical translational value of basic research efforts in humans. We detail modifications to simplified animal paradigms to account for myriad cognitive factors affected in PTSD, which may contribute to abnormalities in regulating fear. We further describe new avenues for integrating different areas of psychological research underserved by animal models of PTSD. This includes incorporating emerging trends in the cognitive neuroscience of episodic memory, emotion regulation, social-emotional processes, and PTSD subtyping to provide a more comprehensive recapitulation of the human experience to trauma in laboratory research.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests Dr. Nemeroff has received research support from NIH; he has served as a consultant for ANeuroTech (division of Anima BV), Signant Health, Magstim, Navitor Pharmaceuticals, Intra-Cellular Therapies, EMA Wellness, Acadia Pharmaceuticals, Sage, BioXcel Therapeutics, Silo Pharma, XW Pharma, Neuritek, Engrail Therapeutics, Corcept Therapeutics Pharmaceuticals Company, SK Life Science, Alfasigma, Pasithea Therapeutic, EcoR1; he has served on scientific advisory boards for ANeuroTech (division of Anima BV), the Brain and Behavior Research Foundation (BBRF), Anxiety and Depression Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Magnolia CNS, Heading Health, TRUUST Neuroimaging, Pasithea Therapeutic; he is a stockholder in Xhale, Seattle Genetics, Antares, BI Gen Holdings, Corcept Therapeutics Pharmaceuticals Company, EMA Wellness, TRUUST Neuroimaging; he serves on the board of directors for Gratitude America, ADAA, Xhale Smart, Lucy Scientific Discovery; and he holds patents on a method and devices for transdermal delivery of lithium (patent 6,375,990B1) and a method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (patent 7,148,027B2). Dr. Fonzo owns equity in Alto Neuroscience.
Figures
References
-
- Ahrenholtz R, Hiser J, Ross MC, Privratsky A, Sartin-Tarm A, James GA, and Cisler JM (2021). Unique neurocircuitry activation profiles during fear conditioning and extinction among women with posttraumatic stress disorder. Journal of Psychiatric Research 141, 257–266. - PubMed
-
- American Psychiatric Association; (2013). Diagnostic and statistical manual of mental disorders (5th ed.), 5th edn (Washington, DC: ).
-
- Anderson MC, Ochsner KN, Kuhl B, Cooper J, Robertson E, Gabrieli SW, Glover GH, and Gabrieli JD (2004). Neural systems underlying the suppression of unwanted memories. Science 303, 232–235. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
